Stock Research for REGN

REGN

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

REGN Stock Chart & Research Data

The REGN chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the REGN chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


REGN Due diligence Resources & Stock Charts

The REGN stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View REGN Detailed Price Forecast - CNN Money CNN View REGN Detailed Summary - Google Finance
Yahoo View REGN Detailed Summary - Yahoo! Finance Zacks View REGN Stock Research & Analysis - Zacks.com


Stock Analysis

TradeIdeas View REGN Trends & Analysis - Trade-Ideas Barrons View REGN Major Holders - Barrons
NASDAQ View REGN Call Transcripts - NASDAQ Seeking View REGN Breaking News & Analysis - Seeking Alpha
Spotlight View REGN Annual Report - CompanySpotlight.com OTC Report View REGN OTC Short Report - OTCShortReport.com
TradeKing View REGN Fundamentals - TradeKing Charts View REGN SEC Filings - Bar Chart
WSJ View Historical Prices for REGN - The WSJ Morningstar View Performance/Total Return for REGN - Morningstar
MarketWatch View the Analyst Estimates for REGN - MarketWatch CNBC View the Earnings History for REGN - CNBC
StockMarketWatch View the REGN Earnings - StockMarketWatch MacroAxis View REGN Buy or Sell Recommendations - MacroAxis
Bullish View the REGN Bullish Patterns - American Bulls Short Pains View REGN Short Pain Metrics - ShortPainBot.com


Social Media Mentions

StockTwits View REGN Stock Mentions - StockTwits PennyStocks View REGN Stock Mentions - PennyStockTweets
Twitter View REGN Stock Mentions - Twitter Invest Hub View REGN Investment Forum News - Investor Hub
Yahoo View REGN Stock Mentions - Yahoo! Message Board Seeking Alpha View REGN Stock Mentions - Seeking Alpha






Financial & Transaction Holdings

SECform4 View Insider Transactions for REGN - SECform4.com Insider Cow View Insider Transactions for REGN - Insider Cow
CNBC View REGN Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for REGN - OTC Markets
Yahoo View Insider Transactions for REGN - Yahoo! Finance NASDAQ View Institutional Holdings for REGN - NASDAQ


Stock Charts

FinViz View REGN Stock Insight & Charts - FinViz.com StockCharts View REGN Investment Charts - StockCharts.com
BarChart View REGN Stock Overview & Charts - BarChart Trading View View REGN User Generated Charts - Trading View


Latest Financial News for REGN

Analysts’ Recommendations for Exelixis in April 2018
Posted on Thursday April 19, 2018

In February 2018, Exelixis (EXEL) and its partner Daiichi Sankyo announced that it had submitted a regulatory application for esaxerenone therapy to the Japanese Pharmaceutical and Medical Devices Agency for the treatment of individuals with hypertension. According to the prior agreement between Exelixis and Daiichi Sankyo, Exelixis is set to receive a milestone payment of $20 million from Daiichi Sankyo. Daiichi Sankyo’s regulatory application has been supported by the results of Phase 3 trials evaluating the safety and efficacy of esaxerenone in individuals with essential hypertension compared to eplerenone.


AbbVie Inc. Is a Clear Value Play in Biotech Stocks
Posted on Tuesday April 17, 2018

Since topping over $120 a share three distinct times since February, shares of AbbVie Inc. (NYSE:ABBV) are still down around 25 percent. Whether the stock was perfectly priced or investors wanted an excuse to lock in profits, ABBV stock still has tremendous value and growth ahead. On March 22, AbbVie reported disappointing Phase 2 data for its Rova-T study that sent its shares lower.


Upadacitinib Could Drive AbbVie’s Long-Term Growth
Posted on Monday April 16, 2018

In April 2018, AbbVie (ABBV) positive results for its Phase 3 SELECT-COMPARE trial, which evaluated the safety and efficacy of upadacitinib for adults with moderate-to-severe rheumatoid arthritis. The trial met its primary endpoint of improved ACR201 scores and clinical remission.


Exploring the Growth of Regeneron’s Praluent
Posted on Thursday April 12, 2018

Regeneron Pharmaceuticals’ (REGN) Praluent is marketed in the United States as an adjunct to diet and maximally tolerated statin therapy for treating adults with heterozygous familial hypercholesterolemia (or HeFH) or clinical atherosclerotic cardiovascular disease (or ASCVD). Praluent is also marketed in Japan and some countries in the European Union. Praluent is a fully human monoclonal antibody inhibitor of PCSK9.


Enter a stock symbol to view the stock details.